Personalized medicine through molecular diagnostics and innovation

Interpace Biosciences is at the forefront of molecular diagnostics, focusing on the early detection and treatment of various cancers, particularly gastrointestinal, endocrine, and lung cancers. The company offers a suite of advanced molecular diagnostic tests, including PancraGEN®, ThyGeNEXT®, and ThyraMIR® v2, which utilize cutting-edge genomic technologies to identify genetic alterations associated with cancer. These tests are designed to assist healthcare providers in determining the most appropriate treatment plans by distinguishing between patients at risk for cancer progression and those who are not. Interpace's proprietary PathFinderTG® platform integrates multiple diagnostic insights, including serum markers and genomic data, to enhance diagnostic accuracy and reduce unnecessary surgical interventions.

The company's product offerings also include RespriDX™, which differentiates between primary and metastatic lung cancer, and BarreGen®, a risk classifier for Barrett's Esophagus that predicts the likelihood of progression to esophageal cancer. Interpace's molecular diagnostic tests are supported by comprehensive reports from experienced molecular pathologists, providing treatment recommendations based on the latest clinical guidelines. By leveraging these innovative technologies, Interpace Biosciences aims to improve patient outcomes through personalized medicine, enabling healthcare providers to make informed decisions regarding patient management and treatment strategies.

United States

Interpace Biosciences develops molecular diagnostic tests under the brand Interpace Diagnostics, and provides clincal trial services under the brand Interpace PharaSolutions.

Interpace Biosciences

Company Details